```json
{
"content": [
{
"type": "paragraph",
"content": "North America leads the Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit market, accounting for 35% of global value. The region benefits from advanced healthcare infrastructure, high adoption of precision oncology, and robust R&D investments. Key drivers include strong reimbursement policies, a mature ecosystem for molecular diagnostics, and rising non-small cell lung cancer (NSCLC) prevalence."
},
{
"type": "paragraph",
"content": "Europe follows with a 30% market share, driven by stringent regulatory frameworks (e.g., IVDR), government-funded cancer screening programs, and collaborations between biotech firms and academic institutions. The fastest-growing region, Asia Pacific, holds 25% share, fueled by expanding healthcare access in China and India, rising awareness of targeted therapies, and partnerships with global diagnostics players."
},
{
"type": "paragraph",
"content": Latin America (8%) and Middle East & Africa (2%) trail due to fragmented infrastructure and limited healthcare budgets. However, growth in Latin America is driven by public-private partnerships to enhance lab networks, while MEA’s market gains momentum from cross-border investments and diagnostic capacity upgrades in key markets like the UAE and South Africa."
},
{
"type": "paragraph",
"content": "The Human EGFR/KRAS/BRAF/PIK3CA/ALK/ROS1 Gene Mutation Detection Kit market growth is projected to accelerate through 2030, with Asia Pacific’s regional forecast outpacing North America and Europe. Strategic acquisitions, AI-driven diagnostics, and decentralized testing models will shape regional dynamics."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 35 },
{ "name": "Europe", "value": 30 },
{ "name": "Asia Pacific", "value": 25 },
{ "name": "Latin America", "value": 8 },
{ "name": "Middle East & Africa", "value": 2 }
]
}
}
```
